Skip to main content
Harm Reduction Resource

Sourcing &
Safety Guide

The question is not whether a supplier has marketing polish. It is whether they can prove identity, purity, sterility, and handling discipline with real documentation.

Research-use-only products are not equivalent to approved medicines.
Fast Triage

Screen suppliers in three passes

Before reading a product page in detail, ask whether the supplier can verify identity, document handling, and show lot-specific testing.

Identity
Mass spec should confirm that the molecule in the vial is the molecule on the label.
Purity
HPLC results should show usable purity, not just marketing language.
Handling
Endotoxin testing, packaging, and cold-chain discipline determine whether a clean synthesis survives delivery.
Supply Chain

Where quality usually breaks

Most failures do not happen at the headline level. They happen in the handoffs between synthesis, testing, packaging, and retail distribution.

01

Raw inputs

Starting materials set the ceiling for purity and sequence fidelity.

02

Synthesis lab

Each coupling step creates opportunities for sequence errors and reagent contamination.

03

Purification

HPLC is where failed sequences and residuals are separated from the target peptide.

04

Testing

Identity, purity, endotoxin, and counterion reporting determine whether the batch is meaningfully characterized.

05

Packaging

Lyophilization, vial sealing, and shipping conditions determine whether a good batch stays good.

COA Reading

What a defensible certificate of analysis should include

A COA is the supplier's strongest quality document. If it is weak, treat every other claim as weaker.

Identity confirmation via mass spectrometry Critical
HPLC purity at or above 98% Critical
Lot-specific data rather than typical results Critical
Independent third-party lab testing Critical
Endotoxin testing for injectables Critical
TFA content reported or removed Useful
Water content reported Useful
Synthesis date and lot number Useful

COA Limitations — Storage conditions during transit, degradation from heat exposure, exact reconstituted concentration, and chain of custody between the tested lot and the shipped vial cannot be confirmed by a COA alone.

TFA Problem — Trifluoroacetate is often introduced during synthesis and can materially reduce how much active peptide is in the vial. Strong suppliers remove it through counterion exchange or disclose its content explicitly.

Supplier Review

Red flags vs positive indicators

This is where the page should feel more like a decision aid than a reference document.

Red Flags
No COA available or only generic typical values
Mass spec missing, so identity is not confirmed
HPLC purity below 97%
No endotoxin testing listed for injectables
Third-party lab not named or not independently verifiable
No physical address or contact information
Claims of pharmaceutical grade without GMP support
Positive Indicators
Independent third-party COA with a verifiable lab
Mass spec plus HPLC in every COA
LAL endotoxin assay included for injectables
TFA removal or content documented
Insulated cold-pack shipping
Lot-specific COAs rather than generic product sheets
Published testing methodology or quality controls
Research Chemical Status

Most research peptides are sold under a research-use-only designation. That does not make them equivalent to approved medicines.

503A Changes

Several popular peptides were removed from 503A pharmacy compounding. Any clinic marketing them as compounded injectables should be scrutinized carefully.

Your Responsibility

Sourcing quality, administration technique, and medical supervision remain the user's responsibility when dealing with research compounds.